Adam Crystal - 01 Oct 2021 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Medical Officer
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
01 Oct 2021
Net transactions value
-$606,738
Form type
4
Filing time
05 Oct 2021, 16:53:11 UTC
Previous filing
02 Aug 2021
Next filing
12 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Options Exercise $74,700 +15,000 $4.98 15,000 01 Oct 2021 Direct
transaction CCCC Common Stock Sale $75,756 -1,712 -11% $44.25* 13,288 01 Oct 2021 Direct F1, F2
transaction CCCC Common Stock Sale $370,563 -8,176 -62% $45.32* 5,112 01 Oct 2021 Direct F1, F3
transaction CCCC Common Stock Sale $235,119 -5,112 -100% $45.99* 0 01 Oct 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Options Exercise $0 -15,000 -8.2% $0.000000 168,108 01 Oct 2021 Common Stock 15,000 $4.98 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.57 to $44.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.85 to $45.845. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.89 to $46.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on September 5, 2020.